Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASNS NASDAQ:ASNS NASDAQ:CGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNSActelis Networks$0.09-7.4%$0.17$0.03▼$8.60$2.22M0.5918.74 million shs270,582 shsASNSActelis Networks$0.09-7.4%$0.17$0.03▼$8.60$2.22M0.5918.74 million shs270,582 shsCGTXCognition Therapeutics$1.25+5.9%$1.10$0.24▼$3.83$105.61M1.75781,206 shs2.48 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNSActelis Networks-7.43%-7.82%-4.44%-54.30%-98.74%ASNSActelis Networks-7.43%-7.82%-4.44%-54.30%-98.74%CGTXCognition Therapeutics+5.93%-0.79%-2.34%+22.55%+420.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNSActelis Networks$0.09-7.4%$0.17$0.03▼$8.60$2.22M0.5918.74 million shs270,582 shsASNSActelis Networks$0.09-7.4%$0.17$0.03▼$8.60$2.22M0.5918.74 million shs270,582 shsCGTXCognition Therapeutics$1.25+5.9%$1.10$0.24▼$3.83$105.61M1.75781,206 shs2.48 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNSActelis Networks-7.43%-7.82%-4.44%-54.30%-98.74%ASNSActelis Networks-7.43%-7.82%-4.44%-54.30%-98.74%CGTXCognition Therapeutics+5.93%-0.79%-2.34%+22.55%+420.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNSActelis Networks 2.00Hold$3.003,388.37% UpsideASNSActelis Networks 2.00Hold$3.003,388.37% UpsideCGTXCognition Therapeutics 2.50Moderate Buy$3.33166.67% UpsideCurrent Analyst Ratings BreakdownLatest CGTX, ASNS, and ASNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2026ASNSActelis Networks Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/31/2026ASNSActelis Networks Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/30/2026ASNSActelis Networks Litchfield Hills ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.003/30/2026ASNSActelis Networks Litchfield Hills ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.003/27/2026CGTXCognition Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026CGTXCognition Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNSActelis Networks$3.67M0.60N/AN/A$0.60 per share0.14ASNSActelis Networks$3.67M0.60N/AN/A$0.60 per share0.14CGTXCognition TherapeuticsN/AN/AN/AN/A$0.39 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNSActelis Networks-$8.26M-$3.96N/AN/AN/A-225.03%-290.78%-111.82%N/AASNSActelis Networks-$8.26M-$3.96N/AN/AN/A-225.03%-290.78%-111.82%N/ACGTXCognition Therapeutics-$23.49M-$0.24N/AN/AN/AN/A-72.68%-53.07%8/6/2026 (Estimated)Latest CGTX, ASNS, and ASNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CGTXCognition Therapeutics-$0.06-$0.05+$0.01-$0.05$4.40 millionN/A3/26/2026Q4 2025CGTXCognition Therapeutics-$0.06-$0.02+$0.04-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNSActelis NetworksN/AN/AN/AN/AN/AASNSActelis NetworksN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNSActelis Networks0.032.461.76ASNSActelis Networks0.032.461.76CGTXCognition TherapeuticsN/A5.925.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNSActelis Networks12.43%ASNSActelis Networks12.43%CGTXCognition Therapeutics43.35%Insider OwnershipCompanyInsider OwnershipASNSActelis Networks0.25%ASNSActelis Networks0.25%CGTXCognition Therapeutics11.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNSActelis Networks4025.80 million26.66 millionN/AASNSActelis Networks4025.80 million26.66 millionN/ACGTXCognition Therapeutics2089.50 million79.56 millionNot OptionableCGTX, ASNS, and ASNS HeadlinesRecent News About These CompaniesCognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at June Financial Conferences on DLB Psychosis Registration ProgramJune 1 at 8:10 AM | quiverquant.comQCognition Therapeutics Participating in Upcoming Investor ConferencesJune 1 at 7:30 AM | globenewswire.comCognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with ...May 21, 2026 | caledonianrecord.comCCognition Therapeutics, Inc. Reports Positive FDA Meeting on Zervimesine Development for Dementia with Lewy Bodies PsychosisMay 21, 2026 | quiverquant.comQCognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with PsychosisMay 21, 2026 | globenewswire.comCognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesMay 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI), 4D Molecular Therapeutics (FDMT) and Cognition Therapeutics (CGTX)May 11, 2026 | theglobeandmail.comCognition Therapeutics (NASDAQ:CGTX) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMay 8, 2026 | marketbeat.comCognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business UpdateMay 8, 2026 | finanznachrichten.deCognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business UpdateMay 7, 2026 | globenewswire.comWhy Cognition Therapeutics, Inc.’s (CGTX) Stock Is Up 5.47%April 28, 2026 | aaii.comAInsider Buying: Cognition Therapeutics (NASDAQ:CGTX) CEO Acquires 9,175 Shares of StockApril 21, 2026 | insidertrades.comCognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at 25th Annual Needham Virtual Healthcare ConferenceApril 7, 2026 | quiverquant.comQCognition Therapeutics to Present at Needham Virtual Healthcare ConferenceApril 7, 2026 | globenewswire.comWhy Cognition Therapeutics, Inc.’s (CGTX) Stock Is Up 12.68%April 1, 2026 | aaii.comACognition Therapeutics CEO Issues Letter to ShareholdersMarch 31, 2026 | globenewswire.comCognition Therapeutics, Inc.: Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development UpdateMarch 26, 2026 | finanznachrichten.deCognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ...March 26, 2026 | finance.yahoo.comCognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comCognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development UpdateMarch 26, 2026 | globenewswire.comCognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial ResultsMarch 23, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGTX, ASNS, and ASNS Company DescriptionsActelis Networks NASDAQ:ASNS$0.09 -0.01 (-7.43%) As of 06/1/2026 03:52 PM EasternActelis Networks, Inc. engages in the design, development, manufacture, and marketing of cyber hardened, hybrid fiber, networking solutions for Internet of Things and telecommunication companies in North America, Europe, the Middle East, Israel, and the Asia Pacific. It provides rapid-deployment networking solutions for wide-area IoT applications, including federal, state, and local governments; intelligent traffic systems; and military, utility, rail, telecom, and campus applications. The company's products include ethernet access devices; network aggregator switches; and Advanced MetaLIGHT/ Gigaline element management systems software, which enables remote management, monitoring, maintenance, and configuration of the installed equipment in the network. It also offers dynamic spectral software; and access broadband equipment. It serves offers its products through system integrators, distributors, contractors, resellers, and consultants. The company was incorporated in 1998 and is headquartered in Fremont, California.Actelis Networks NASDAQ:ASNS$0.09 -0.01 (-7.43%) As of 06/1/2026 03:52 PM EasternActelis Networks, Inc. engages in the design, development, manufacture, and marketing of cyber hardened, hybrid fiber, networking solutions for Internet of Things and telecommunication companies in North America, Europe, the Middle East, Israel, and the Asia Pacific. It provides rapid-deployment networking solutions for wide-area IoT applications, including federal, state, and local governments; intelligent traffic systems; and military, utility, rail, telecom, and campus applications. The company's products include ethernet access devices; network aggregator switches; and Advanced MetaLIGHT/ Gigaline element management systems software, which enables remote management, monitoring, maintenance, and configuration of the installed equipment in the network. It also offers dynamic spectral software; and access broadband equipment. It serves offers its products through system integrators, distributors, contractors, resellers, and consultants. The company was incorporated in 1998 and is headquartered in Fremont, California.Cognition Therapeutics NASDAQ:CGTX$1.25 +0.07 (+5.93%) Closing price 06/1/2026 04:00 PM EasternExtended Trading$1.35 +0.10 (+8.16%) As of 05:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
